Tak1-inhibitors did not reduce disease burden in a vκ*myc model of multiple myeloma

HIGHLIGHTS

• who: Erling Hu00e5land from the (UNIVERSITY) have published the research work: TAK1-inhibitors did not reduce disease burden in a Vu03ba*MYC model of multiple myeloma, in the Journal: (JOURNAL)
• what: Development of resistance and minimal residual disease remain challenging in the treatment of Transforming growth factor-u03b2 activated kinase 1 (TAK1) has recently gained attention as a potential drug target in This study aimed at determining the in vivo effects of TAK1-inhibitors in a Vu03ba MYC mouse model. The authors investigated the in_vivo effect of TAK1 inhibitors NG25 and 5Z-7 in the . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.